What insurance policy changes affect HCPCS J9119?

There are 7 tracked policy changes affecting HCPCS J9119, including updates from Humana, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9119?

Payers that have issued tracked updates for HCPCS J9119 include: Humana, Independence Blue Cross.

How do I get notified when HCPCS J9119 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9119. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9119?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9119 Insurance Policy Changes

HCPCS J9119 is officially defined as "Injection, cemiplimab-rwlc, 1 mg." HCPCS J9119 is referenced in 7 tracked payer policy changes from Humana and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9119 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Breyanzi® (lisocabtagene maraleucel) (Revised)
Humana·Effective May 1, 2026
This is a revision to Humana's Kentucky Medicaid prior authorization policy for Breyanzi® (lisocabtagene maraleucel), a CAR-T cell therapy for relapsed/refractory B-cell lymphomas and CLL/SLL. The policy outlines specific clinical criteria, exclusions, and a one-dose-per-lifetime approval limit for multiple indications. The revision date of May 1, 2026 indicates this is an updated version of the original April 21, 2021 policy.
High impact
Asparlas™ (calaspargase pegol-mknl) (Revised)
Humana·Identified Jul 22, 2026
This is a revised Prior Authorization policy for Asparlas™ (calaspargase pegol-mknl), a chemotherapy agent used in acute lymphoblastic leukemia treatment. The policy applies to Medicare, Medicaid programs in Florida, Kentucky, and South Carolina. Specific policy details are unavailable in the summary-only format, so the billing team must access the full policy document to identify exact authorization requirements and any changes from previous versions.
Medium impact
Yescarta™ (axicabtagene ciloleucel) (Revised)
Humana·Effective May 1, 2026
Humana Kentucky Medicaid updated its Yescarta (axicabtagene ciloleucel) prior authorization policy effective May 1, 2026. The policy covers CAR-T cell therapy for relapsed/refractory large B-cell lymphoma (2L and 3L indications) and follicular lymphoma in adults ≥18 years. Key requirements include prior authorization through Corporate Transplant Department, use with lymphodepleting chemotherapy, and exclusions for prior CD-19 targeted therapy, active hepatitis B/C, HIV/AIDS, and prior allogeneic transplant. Maximum one dose per lifetime applies.
Medium impact
Vyxeos™ (daunorubicin and cytarabine) liposome (New)
Humana·Effective May 1, 2026
Humana Medicaid Louisiana has established a NEW prior authorization policy (effective May 1, 2026) for Vyxeos (daunorubicin and cytarabine) liposome injection. Coverage is limited to adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), and approvals are capped at 2 cycles of induction plus 2 cycles of consolidation per 6-month authorization period. Claims will be denied if the member has experienced prior disease progression on Vyxeos or conventional daunorubicin/cytarabine regimens.
Medium impact
MA08.163d, Glofitamab-gxbm (Columvi)
Independence Blue Cross·Effective Jul 28, 2025
Policy MA08.163d establishes medical necessity criteria for Glofitamab-gxbm (Columvi), a chimeric antigen receptor (CAR) T-cell therapy. This recent policy change updates coverage requirements and prior authorization guidelines for this specialty pharmacy drug effective July 28, 2025. Billing teams must verify all claims meet the specified medical necessity criteria before submission.
Medium impact
08.02.07d, Glofitamab-gxbm (Columvi)
Independence Blue Cross·Effective Jul 28, 2025
Policy 08.02.07d has been updated with new medical necessity criteria for Glofitamab-gxbm (Columvi), a pharmaceutical treatment. The billing team must implement these updated criteria to ensure claims meet coverage requirements and avoid denials.
Medium impact
Kimmtrak (tebentafusp-tebn) (Revised)
Humana·Identified Jul 21, 2026
Humana Medicaid-Louisiana has issued a revised Prior Authorization policy for Kimmtrak (tebentafusp-tebn), a bispecific protein immunotherapy. This update requires prior authorization before billing this drug for Louisiana Medicaid members. Billing teams must implement authorization verification workflows to prevent claim denials.

All billing codes J3590 99212 99213 99202 99211 99214

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Breyanzi® (lisocabtagene maraleucel) (Revised)

Asparlas™ (calaspargase pegol-mknl) (Revised)

Yescarta™ (axicabtagene ciloleucel) (Revised)

Vyxeos™ (daunorubicin and cytarabine) liposome (New)

MA08.163d, Glofitamab-gxbm (Columvi)

08.02.07d, Glofitamab-gxbm (Columvi)

Kimmtrak (tebentafusp-tebn) (Revised)